Stockreport

Merck Keytruda combo meets main goal in late-stage trial for advanced gastric cancer [Seeking Alpha]

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF The Phase 3 KEYNOTE-811 trial, evaluating Merck's anti-PD-1 therapy Keytruda (pembrolizumab) in combination with trastuzumab and fluoropyrimidine- and platinum-containi [Read more]